Insights on the Cell Therapy Global Market to 2027 - by Cell Type, Therapy Type, Therapeutic Area, End-user and Region

DUBLIN, Dec. 9, 2022 /PRNewswire/ -- The "Cell Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to  ResearchAndMarkets.com's offering.

The global cell therapy market size reached US$ 9.17 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 27.05 Billion by 2027, exhibiting a CAGR of 19.76% during 2021-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Cell therapy (CT) is the transplantation of human cells to replace or repair damaged tissues and cells. It comprises hematopoietic stem cells (HSC), skeletal muscle and mesenchymal stem cells, lymphocytes, and dendritic and pancreatic islet cells. It improves the immune system of the body to fight cancer cells.

Apart from this, cell therapy assists in treating various conditions, such as autoimmune and infectious diseases, urinary problems, damaged cartilage in joints, spinal cord injuries, a weakened immune system, and neurological disorders. At present, it is used to manufacture regenerative medicines for developing and applying new treatments to heal tissues and organs and restore functions lost due to aging, disease, and damage.

Cell Therapy Market Trends:

At present, there is a rise in the prevalence of various diseases, such as cancer and cardiac abnormalities, across the globe. This, along with the growing number of clinical studies for cell-based therapies, represents one of the key factors driving the market. Besides this, governing agencies of several countries are promoting clinical trials around the world, which is contributing to the growth of the market.

In addition, key market players are extensively investing in research and development (R&D) activities to introduce skin rejuvenation and tendon regeneration therapies. They are also focusing on developing direct cell reprogramming to replace lost neuronal tissues due to neurodegeneration or neurotrauma.

Moreover, there is an increase in the development of advanced genomic therapy techniques to treat various diseases, such as cystic fibrosis, heart disease, diabetes, hemophilia, and acquired immune deficiency syndrome (AIDS). This, coupled with the burgeoning healthcare industry, is propelling the growth of the market.

Apart from this, the rising demand for regenerative medicines to replace tissue or organs damaged by diseases, traumas, or congenital issues is bolstering the growth of the market.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AlloSource, Anterogen Co. Ltd., Cells for Cells, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals, Kolon TissueGene Inc., MEDIPOST, Mesoblast Limited, NuVasive, Stemedica Cell Technologies Inc., Stempeutics Research Pvt. Ltd and Vericel Corporation.

Key Questions Answered in This Report:

• How has the global cell therapy market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global cell therapy market?
• What are the key regional markets?
• What is the breakup of the market based on the cell type?
• What is the breakup of the market based on the therapy type?
• What is the breakup of the market based on the therapeutic area?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global cell therapy market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Cell Therapy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Cell Type
6.1 Stem Cell
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Bone Marrow
6.1.2.2 Blood
6.1.2.3 Umbilical Cord-Derived
6.1.2.4 Adipose-Derived Stem Cell
6.1.2.5 Others
6.1.3 Market Forecast
6.2 Non-stem Cell
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Therapy Type
7.1 Autologous
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Allogeneic
7.2.1 Market Trends
7.2.2 Market Forecast

8 Market Breakup by Therapeutic Area
8.1 Malignancies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Musculoskeletal Disorders
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Autoimmune Disorders
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Dermatology
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast

9 Market Breakup by End User
9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Academic and Research Institutes
9.2.1 Market Trends
9.2.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 AlloSource
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.2 Anterogen Co. Ltd.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.3 Cells for Cells
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.4 Holostem Terapie Avanzate S.r.l.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5 JCR Pharmaceuticals
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Kolon TissueGene Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.7 MEDIPOST
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.8 Mesoblast Limited
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.9 NuVasive
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Stemedica Cell Technologies Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.11 Stempeutics Research Pvt. Ltd
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.12 Vericel Corporation
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ehz383

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets